- Home
- NUVL vs CPRI Comparison
NUVL vs CPRI Comparison
Compare NUVL & CPRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- CPRI
- Stock Information
- Founded
- NUVL 2017
- CPRI 1981
- Country
- NUVL United States
- CPRI United Kingdom
- Employees
- NUVL N/A
- CPRI N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- CPRI Apparel
- Sector
- NUVL Health Care
- CPRI Consumer Discretionary
- Exchange
- NUVL Nasdaq
- CPRI Nasdaq
- Market Cap
- NUVL 4.9B
- CPRI 5.0B
- IPO Year
- NUVL 2021
- CPRI 2011
- Fundamental
- Price
- NUVL $87.24
- CPRI $20.82
- Analyst Decision
- NUVL Strong Buy
- CPRI Hold
- Analyst Count
- NUVL 10
- CPRI 7
- Target Price
- NUVL $112.60
- CPRI $30.29
- AVG Volume (30 Days)
- NUVL 492.9K
- CPRI 9.3M
- Earning Date
- NUVL 11-12-2024
- CPRI 11-07-2024
- Dividend Yield
- NUVL N/A
- CPRI N/A
- EPS Growth
- NUVL N/A
- CPRI N/A
- EPS
- NUVL N/A
- CPRI N/A
- Revenue
- NUVL N/A
- CPRI $4,796,000,000.00
- Revenue This Year
- NUVL N/A
- CPRI N/A
- Revenue Next Year
- NUVL N/A
- CPRI $1.85
- P/E Ratio
- NUVL N/A
- CPRI N/A
- Revenue Growth
- NUVL N/A
- CPRI N/A
- 52 Week Low
- NUVL $56.52
- CPRI $18.70
- 52 Week High
- NUVL $113.51
- CPRI $51.23
- Technical
- Relative Strength Index (RSI)
- NUVL 38.02
- CPRI 24.76
- Support Level
- NUVL $89.62
- CPRI $18.70
- Resistance Level
- NUVL $96.24
- CPRI $21.25
- Average True Range (ATR)
- NUVL 2.90
- CPRI 1.01
- MACD
- NUVL -0.27
- CPRI 0.16
- Stochastic Oscillator
- NUVL 15.96
- CPRI 42.17
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About CPRI Capri Holdings Limited
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Michael Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.